Brief Title
The Plasma Serotonin and Aortic Stenosis: a Pilot Study.
Official Title
The Plasma Serotonin and Aortic Stenosis: a Pilot Study.
Brief Summary
The goal of this study is to describe the increase in plasma serotonin or 5-hydroxytryptamine (5-HT) in patient with increased severity of aortic stenosis and increased weight cardiac muscle.
Detailed Description
Calcific aortic stenosis is the most frequent valve disease in adults. Without therapeutic strategy, this disease leads to heart failure and death. Surgical aortic valve replacement is now a well tolerated cardiac surgery leading to excellent outcomes. Until recently, calcific aortic stenosis was considered to be histopathologically degenerative or passive in origin. It is now recognized, however, as a complex cellular process with features of atherosclerosis. It has been observed that drugs may slow dawn the progression of aortic stenosis in observational studies. It has been suggested that serotonin, a monoamine neurotransmitter and a peripheral signal mediator, may be involved in the progression of aortic stenosis and also in its consequences on myocardium hypertrophy. In the blood, serotonin in mainly stored in platelets, which release serotonin involved in post-injury vasoconstriction, thrombus formation, fibrosis and atherogenesis. This study hypothesized those patients with aortic stenosis exhibit higher circulating serotonin levels than their counterparts without heart disease. In addition to circulating serotonin, its metabolite 5-HIAA will be systematically measured on all patients. This study would allow to determine the potential of plasma serotonin as a prognosis marker and perhaps suggest the discovery of new targets for treatment of aortic stenosis.
Study Type
Interventional
Primary Outcome
Measurements of 5-HT
Secondary Outcome
Measurements of acide 5-hydroxy-indol-acetic (5-HIAA)
Condition
Aortic Stenosis
Intervention
biomarkers
Study Arms / Comparison Groups
Group 1
Description: Control group had biomarkers.
Publications
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
Recruitment Information
Recruitment Status
Procedure
Estimated Enrollment
52
Start Date
February 2010
Completion Date
September 2012
Primary Completion Date
September 2012
Eligibility Criteria
Inclusion Criteria: - Group 1 : non aortic stenosis - Goup 2, 3 and 4 : aortic stenosis Exclusion Criteria: -
Gender
All
Ages
18 Years - N/A
Accepts Healthy Volunteers
No
Contacts
Olivier Lairez, MD, ,
Location Countries
France
Location Countries
France
Administrative Informations
NCT ID
NCT02833090
Organization ID
09 238 03
Responsible Party
Sponsor
Study Sponsor
University Hospital, Toulouse
Study Sponsor
Olivier Lairez, MD, Principal Investigator, University Hospital, Toulouse
Verification Date
May 2017